Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy
2024

MRI Biomarker for Prognosis in IgA Nephropathy

Sample size: 112 publication Evidence: moderate

Author Information

Author(s): Wang Zitao, Jiang Ling, Lu Fang, Qian Li, Pan Ying, Zhang Chengning, Huang Zhimin, Zeng Ming, Sun Bin, Zhang Bo, Mao Huijuan, Zhang Yudong, Duan Suyan, Xing Changying, Yuan Yanggang

Primary Institution: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Hypothesis

The study aims to explore the association of the cortico-medullary difference in apparent diffusion coefficient (ΔADC) with clinicopathological parameters and prognostic risk stratification in IgA nephropathy patients.

Conclusion

ΔADC is significantly associated with kidney function and can predict a high 5-year kidney progression risk in IgAN patients.

Supporting Evidence

  • ΔADC levels decreased significantly with increasing chronic kidney disease stages (p=0.0038).
  • ΔADC was positively correlated with eGFR, hemoglobin, and serum albumin.
  • Low ΔADC was associated with a 7.509-fold higher likelihood of higher progression risk compared to high ΔADC.

Takeaway

Doctors can use a special MRI measurement called ΔADC to see how likely it is that patients with a kidney disease called IgA nephropathy will get worse over the next five years.

Methodology

112 patients with biopsy-proven IgAN underwent kidney biopsy and diffusion-weighted MRI within one week, and clinicopathological characteristics were compared according to different ΔADC levels.

Limitations

The study was monocentric with a relatively small sample size and focused only on IgAN without comparing multiple kidney functional MRI parameters.

Participant Demographics

Mean age of 40.04 years, with a gender distribution of 55 males and 57 females.

Statistical Information

P-Value

p=0.033

Confidence Interval

[0.003, 0.077]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1080/0886022X.2024.2441394

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication